Participation in a Research Registry for Immune Disorders
Learn more about:
Related Clinical Trial
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Participation in a Research Registry for Immune Disorders
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome
Gene Therapy for WAS
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
Molecular and Clinical Studies of Primary Immunodeficiency Diseases
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients